These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? Motta I; Calcagno A; Bonora S Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):59-82. PubMed ID: 29226732 [TBL] [Abstract][Full Text] [Related]
24. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach. Pienaar E; Sarathy J; Prideaux B; Dietzold J; Dartois V; Kirschner DE; Linderman JJ PLoS Comput Biol; 2017 Aug; 13(8):e1005650. PubMed ID: 28817561 [TBL] [Abstract][Full Text] [Related]
25. New approaches to the treatment of latent tuberculosis. Sterling TR Semin Respir Crit Care Med; 2008 Oct; 29(5):532-41. PubMed ID: 18810686 [TBL] [Abstract][Full Text] [Related]
26. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Ena J; Valls V Clin Infect Dis; 2005 Mar; 40(5):670-6. PubMed ID: 15714411 [TBL] [Abstract][Full Text] [Related]
27. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm. Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768 [TBL] [Abstract][Full Text] [Related]
28. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society. Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420 [TBL] [Abstract][Full Text] [Related]
30. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Ahmad Z; Sharma S; Khuller GK Int J Antimicrob Agents; 2005 Oct; 26(4):298-303. PubMed ID: 16154726 [TBL] [Abstract][Full Text] [Related]
31. Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis. Mitchison DA Am J Respir Crit Care Med; 2003 May; 167(10):1298-9. PubMed ID: 12738593 [No Abstract] [Full Text] [Related]
32. Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens. Lambert LA; Ijaz K; Navin TR Int J Tuberc Lung Dis; 2005 Feb; 9(2):230; author reply 230-1. PubMed ID: 15732748 [No Abstract] [Full Text] [Related]
33. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels. Roy V; Tekur U; Chopra K Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902 [TBL] [Abstract][Full Text] [Related]
34. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943 [TBL] [Abstract][Full Text] [Related]
35. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Weiner M; Burman W; Vernon A; Benator D; Peloquin CA; Khan A; Weis S; King B; Shah N; Hodge T; Am J Respir Crit Care Med; 2003 May; 167(10):1341-7. PubMed ID: 12531776 [TBL] [Abstract][Full Text] [Related]
36. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Jeena PM; Bishai WR; Pasipanodya JG; Gumbo T Antimicrob Agents Chemother; 2011 Feb; 55(2):539-45. PubMed ID: 21098246 [TBL] [Abstract][Full Text] [Related]
37. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. Reves R; Heilig CM; Tapy JM; Bozeman L; Kyle RP; Hamilton CD; Bock N; Narita M; Wing D; Hershfield E; Goldberg SV; Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795 [TBL] [Abstract][Full Text] [Related]
38. The pharmacokinetics of a single oral or rectal dose of concurrently administered isoniazid, rifampin, pyrazinamide, and ethambutol in Asian elephants (Elephas maximus). P Brock A; Isaza R; Egelund EF; Hunter RP; Peloquin CA J Vet Pharmacol Ther; 2014 Oct; 37(5):472-9. PubMed ID: 24684601 [TBL] [Abstract][Full Text] [Related]
39. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model. Lyons MA; Lenaerts AJ J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):375-89. PubMed ID: 26026426 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins. Mitchison DA Int J Tuberc Lung Dis; 2012 Sep; 16(9):1186-9. PubMed ID: 22794180 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]